Amgen (AMGN) 10-K Summary — Year Ended Dec 31, 2023

Amgen is a biotechnology company focused on innovative medicines. The filing reports revenue growth and strong operating cash flow for the period.

Key takeaway

Year ended Dec 31, 2023 · FY2025 10-K

Amgen is a biotechnology company focused on innovative medicines. The filing reports revenue growth and strong operating cash flow for the period.

Financial snapshot

Selected annual figures reported with the filing, shown separately from the narrative summary.

Annual revenue

$28.2B

Revenue reported for the fiscal year.

Operating income

$7.9B

Income from operations reported for the year.

Net income

$6.7B

Net income reported for the year.

Operating cash flow

$8.5B

Cash generated by operating activities.

Annual revenue trend

Reported annual revenue and its change from the preceding fiscal year.

Period ended	Revenue	Year-over-year change
Dec 31, 2021	$26B	n/a
Dec 31, 2022	$26.3B	+1.3%
Dec 31, 2023	$28.2B	+7.1%

Business overview

Amgen discovers, develops, manufactures, and delivers innovative medicines to address high unmet medical needs. The company has a robust pipeline of potential first-in-class medicines and markets a broad portfolio of products including Prolia, ENBREL, and Otezla. It is one of the world's leading independent biotechnology companies with over 40 years of history.

Financial performance

Revenue increased compared to the prior year, contributing to a positive operating income and net income. Operating cash flow also remained strong.

Material risks

The filing includes a risk factors section (Item 1A) but the supplied context does not provide specific risk details. The document notes that forward-looking statements are subject to uncertainties.

Liquidity and capital

The company discusses liquidity and capital resources, including planned dividends and stock repurchases. Operating cash flow supported these activities.

What to watch

Monitor the progress of the company's pipeline of potential first-in-class medicines.